M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 23 of 54
A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
NCT06199466
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
NCT06046482
A Pilot Clinical Trial to Determine the Feasibility of Administering an Electronic Tool to Assess Postoperative pAin, Nausea, and Vomiting in English or Spanish-Speaking Pediatric Patients With Neoplastic Conditions.
NCT05933252
A Virtually Delivered Exercise Intervention To Mitigate Cognitive Deficits From Radiotherapy In AYAs With Brain Tumors
NCT05554159
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
NCT05464836
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
NCT05634577
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
NCT05717400
Vapocoolant Analgesia for Breast Lymphoscintigraphy
NCT05744557
Implementation of Digital Vital Sign Monitoring to Decrease Sleep Interruption and Enhance Recovery in Phase II of the PROmoting Sleep, Patient Engagement and Recovery (PROSPER) Project
NCT05456360
Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status
NCT05634551
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
NCT05065047
Sexual Dysfunction in Palliative Care Patients: An Assessment of Patient's Perspective
NCT05837117
Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Central Lung Tumors
NCT05609331
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
NCT05317936
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
NCT05082025
A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma
NCT05322135
Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule
NCT05003856
A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)
NCT05466994
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
NCT05243641
Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT04835597
A Pilot Study Assessing the Effectiveness of Use of Guided Imagery for Treatment of Pain and Symptom Management in Women With Post-mastectomy Pain Syndrome
NCT05408741
Gender Differences in Switching From Smoking Regular Cigarettes to E-Cigarettes
NCT03856515
Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial
NCT05328973
POWER UP: Participating Online While Exercising to Recover Using Play
NCT05308407
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
NCT04904302
Single Step Lesion Annotation and Localization of Suspicious Breast Lesions
NCT05118295
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
NCT05115630
Attitudes and Believes About Vaccinations in a Supportive Care Patient Population
NCT05329506
A Phase IB Study OF Immunotherapy With EX Vivo Pre-activated AND Expanded Cb-nk Cells IN Combination With Cetuximab, IN Colorectal Cancer Patients With Minimal Residual Disease (MRD)
NCT05040568
Development of an Application-Based Digital Navigator for Perioperative Breast Surgery Patients
NCT05290402
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT05032183
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
NCT05059470
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
NCT05041101
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
NCT04874194
Positive Activities for Asian American Cancer Patients and Caregivers
NCT05203614
DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease
NCT05036109
Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant
NCT04239989
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
NCT05036681
Phase II Single-center, Randomized, Open-label, Prospective, Study TO Determine THE Impact OF Serial Procalcitonin
NCT04983901
Sintilimab in Cancer of Unknown Primary
NCT05024968
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
NCT05026736
Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
NCT05030675
Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy
NCT05083338
An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
NCT04978675
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
NCT04754425
Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study
NCT05017103
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
NCT04971187
Feasibility of Digital Thermal Monitoring to Assess Endothelium-Dependent Vasodilation in Patients Undergoing Hematopoietic Cell Transplantation (HCT)
NCT05029752
Use of Google Translate to Enhance Patient Pain and Nausea Assessment and Satisfaction After General Anesthesia
NCT05060328
Multicomponent Physical Activity Intervention for the Reduction of Psychosocial Distress in Cancer Patients
NCT05056831
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.